Your session is about to expire
← Back to Search
Antioxidant
Oral and IV N acetyl Cysteine Cohort for Parkinson's Disease
N/A
Waitlist Available
Led By Daniel A Monti, MD,MBA
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Clinical Diagnosis of Parkinson's disease
Subject is between 30 - 80 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 90 ± 30 days
Awards & highlights
Study Summary
This trial is testing whether NAC, a compound with antioxidant and anti-inflammatory effects, can help improve brain function in patients with Parkinson's disease.
Eligible Conditions
- Parkinson's Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and 90 ± 30 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 90 ± 30 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Changes in the dopamine transporter (DAT) which reflects the overall health of the dopaminergic system
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Oral and IV N acetyl Cysteine CohortExperimental Treatment1 Intervention
Administration of Intravenous (IV) and Oral N-acetyl Cysteine (NAC) Intervention: IV NAC infusion: Dose: 50mg in 200ml of D5W, frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 600 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
Group II: Control CohortActive Control1 Intervention
Standard of Care Treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Intravenous and Oral n-acetyl cysteine
2014
N/A
~60
Find a Location
Who is running the clinical trial?
Thomas Jefferson UniversityLead Sponsor
445 Previous Clinical Trials
145,663 Total Patients Enrolled
Daniel A Monti, MD,MBAPrincipal InvestigatorThomas Jefferson University
1 Previous Clinical Trials
80 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
New Jersey
How old are they?
18 - 65
What site did they apply to?
Thomas Jefferson University
What portion of applicants met pre-screening criteria?
Met criteria
Share this study with friends
Copy Link
Messenger